PDCD1LG2 and lymphoma: NCT02812875 is a study of CA-170 (a small molecule) directly targeting the PD-L1/PD-L2 as well as VISTA immune checkpoints in adult patients with advanced solid tumors or lymphomas who have progressed or are non-responsive to available therapies and for which no standard therapy exists.